Stocktoria
Immunovant, Inc. IMVT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-05-14
Immunovant, Inc. statistics & valuation
Market cap$8.0B
P / B9.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Return on assets | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% |
| Return on equity | -59.3% | -58.5% | -42.0% | -58.2% | -33.4% |
| Current ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 |
Source: SEC EDGAR filings · CIK 0001764013 · as of 2026-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.